Vanda Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review HETLIOZ™ NDA
WASHINGTON, Nov. 14, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that NASDAQ halted trading of Vanda common stock this morning.
The Peripheral and Central Nervous System Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) meets today to review Vanda's New Drug Application (NDA) for tasimelteon, proposed trade name HETLIOZ™, for the treatment of Non-24-Hour Disorder in the totally blind. The Advisory Committee meeting is scheduled for 8:00 am ET.
Vanda's HETLIOZ™ NDA is currently under Priority Review by the FDA with an action target date under the Prescription Drug User Fee Act (PDUFA-V) of January 31, 2014.
The Trout Group
Assistant Vice President
SOURCE Vanda Pharmaceuticals Inc.
More by this Source
Vanda Pharmaceuticals Reports Fourth Quarter 2013 and Full Year 2013 Results
Feb 13, 2014, 07:00 ET
FDA Approves HETLIOZ™ (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder
Jan 31, 2014, 13:45 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.